Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma

NCT ID: NCT07276230

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-01

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The diagnosis and treatment of multiple myeloma affect not only the patient but also their family and caregivers. Advances in therapy have transformed the follow-up of patients treated for multiple myeloma. The involvement of informal caregivers has become increasingly essential to ensure adequate home-based care, as most treatments are now delivered on an outpatient basis. Literature reviews suggest that caregivers of cancer patients often face unmet supportive care needs, which in turn negatively impact their quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

By improving the quality of life of caregivers, the intervention can help prevent cascading effects such as a deterioration in the quality of life of the care recipient, thereby reducing the overall burden on healthcare systems. In addition, therapeutic education is an ongoing process aimed at helping patients and/or caregivers acquire or maintain the skills they need to best manage their lives with a chronic condition.

Study procedures :

1. During the hematology consultation, the study will be presented to the caregiver identified by the patient (between Day -7 and Day 0). After receiving full oral and written information, the caregiver's free, written, and informed consent will be obtained prior to participation.
2. After providing written informed consent to participate in the study, the caregiver will attend an individual interview at Day 0 with a nurse to complete a Shared Educational Assessment .The caregiver will then independently complete a self-administered questionnaire assessing quality of life using the CarGOQoL (CareGiver Oncology Quality of Life).

The Shared Educational Assessment is a discussion between the healthcare professional and the caregiver focusing on the skills to be acquired or strengthened in order to improve health and quality of life. It enables exploration and assessment of the caregiver's needs and resources in terms of :
* Acquisition of knowledge;
* Acquisition or reinforcement of self-care and coping skills, while recognizing and valuing the caregiver's own self learning efforts.
3. The group of caregivers thus constituted will attend four therapeutic education workshops. Each workshop will last approximately 1 hour and 30 minutes. Caregivers will attend two half-day sessions, participating in two workshops per session (Week 1: Workshops 1 \& 2; Week 2: Workshops 3 \& 4).

The topics addressed in the workshops are as follows:
* Workshop 1: Understanding the disease
* Workshop 2: Identifying abnormalities in biological tests and adapting the appropriate response
* Workshop 3: Understanding treatments and their adverse effects
* Workshop 4: Expressing personal experiences and feelings caregivers' satisfaction with each workshop will be assessed at the end of every session
4. At the end of the program (three months after inclusion), the caregiver will attend a follow-up consultation with the nurse to evaluate skill acquisition and will independently complete the same quality of life questionnaire (CarGOQoL) that was administered prior to the program
5. At six months, a new assessment of quality of life will be conducted using the CarGOQoL questionnaire during a telephone interview with a member of the investigative team

The questionnaire will be available in paper format, and the responses will be entered into an electronic case report form (e-CRF) using the CleanWeb system. The data will be analyzed by the Clinical Research Unit (URC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Caregivers of Patients With Multiple Myeloma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

caregivers multiple myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Caregivers of patients followed for multiple myeloma during first-line therapy
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caregivers

Therapeutic Education and Needs Assessment Program for Caregivers of Patients with Multiple Myeloma

Group Type EXPERIMENTAL

Therapeutic Education and Needs Assessment Program for Caregivers

Intervention Type OTHER

Participation in a weekly therapeutic education group for 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Therapeutic Education and Needs Assessment Program for Caregivers

Participation in a weekly therapeutic education group for 4 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Caregiver :

* Designated by a patient followed for multiple myeloma during first-line treatment
* Providing weekly assistance to the patient (e.g., shopping, housekeeping, management of daily living activities, healthcare or hygiene support, etc.)
* Aged 18 years or older
* Fluent in French
* Affiliated with or benefiting from a social security system (excluding state medical aid - AME)
* Able to provide free, written, and informed consent

Exclusion Criteria

Caregiver :

* Not designated by the patient as the primary caregiver
* Currently being treated for an acute medical condition
* Refusal of the caregiver to participate in the study
* Under legal protection (guardianship or curatorship)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne LE BORGNE, Mrs

Role: PRINCIPAL_INVESTIGATOR

Hospital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hématologie clinique - Pitié-Salpêtrière Hospital (APHP)

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anne LE BORGNE, Mrs

Role: CONTACT

Phone: 01 84 82 83 15

Email: [email protected]

Laurent Dr GARDERET, MD

Role: CONTACT

Phone: 01 42 16 27 94

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anne LE BORGNE, Mrs

Role: primary

Laurent Dr GARDERET, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP250083

Identifier Type: -

Identifier Source: org_study_id